Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 200Neoplasms 116Breast Neoplasms 112Colorectal Neoplasms 97Ovarian Neoplasms 78Prostatic Neoplasms 75Neoplasm Metastasis 74Lung Neoplasms 66Multiple Myeloma 64Squamous Cell Carcinoma of Head and Neck 49Pancreatic Neoplasms 48Endometrial Neoplasms 48Recurrence 46Stomach Neoplasms 39Carcinoma, Renal Cell 39Small Cell Lung Carcinoma 38Melanoma 38Leukemia, Lymphocytic, Chronic, B-Cell 38Leukemia, Myeloid, Acute 34Lymphoma, Non-Hodgkin 30Urinary Bladder Neoplasms 29Parkinson Disease 4, Autosomal Dominant Lewy Body 29Triple Negative Breast Neoplasms 28Head and Neck Neoplasms 26Carcinoma, Hepatocellular 26Lymphoma, Large B-Cell, Diffuse 25Lymphoma, Follicular 25Esophageal Neoplasms 24Advanced Solid Tumors 24Lymphoma 23

Interventions

Rosuvastatin Calcium 1Metformin 1Digoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Drug-drug Interaction,SHR3680 × 30 days × Clear all
NCT04621669 2026-06-05

Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
36 enrolled

Drug-drug Interaction,SHR3680

Data powered by HemOnc (CC BY 4.0) Colophon âš¡